Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up
Authors' conclusion
This study brings new knowledge on the relationship between the absorbed dose to the salivary glands from 131I-therapy and salivary/lacrimal dysfunctions in DTC patients six months after 131I-therapy. Despite the findings of some dysfunctions, the results do not show any obvious clinical disorders after the 131I-therapy.
Study context
- Population
- Differentiated thyroid cancer (DTC) patients treated by 131I-therapy; salivary/lacrimal functions assessed at baseline (immediately before 131I-therapy) and 6 months later
- Participants
- 136 patients
- Exposure
- 131I-therapy 1.1 GBq vs 3.7 GBq; T6 vs T0
- 1.1 GBqn = 44
- 3.7 GBqn = 92
- Outcome
- Salivary/lacrimal dysfunction, T6 vs T0
- Follow-up
- 6 months
Main finding
As reported in the abstract
- No difference between T0 and T6 in parotid gland pain level
- No difference in number of patients with hyposalivation
- Significantly more patients with dry mouth sensation and dry eyes after therapy vs baseline
Observational data: associations, not effects.
Further findings
| Outcome | OR (CI) | |
|---|---|---|
| Dose-response: per 1-Gy increase in mean dose to salivary glands, adjusted · 6 monthsPer 1-Gy increase in mean salivary gland dose · dry mouth sensation | 1.43 (1.02–2.04) | |
| 0.512Odds ratio (log scale) |
| Outcome | Estimate |
|---|---|
| Dose-response: per 1-Gy increase in mean dose to salivary glands, adjusted · 6 monthsPer 1-Gy increase in mean salivary gland dose · stimulated saliva flow | ß −0.08 mL/min (CI −0.12 to −0.02) |
| Dose-response: per 1-Gy increase in mean dose to salivary glands, adjusted · 6 monthsPer 1-Gy increase in mean salivary gland dose · salivary potassium concentration | ß 1.07 mmol/L (CI 0.42–1.71) |
- Dose-response: per 1-Gy increase in mean dose to salivary glands, adjusted: adjusted on age, menopause, depression and anxiety symptoms, history of systemic disease, painkiller use
Risk factors for salivary or lacrimal disorders
- Age, menopause, depression and anxiety symptoms, history of systemic disease, and not taking painkillers in past 3 months significantly associated with salivary or lacrimal disorders
Original publication
Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up. Thyroid. Published 23 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →